Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Application of Metal-Based Complexes in Cancer Treatment
share announcement

Application of Metal-Based Complexes in Cancer Treatment

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".

Deadline for manuscript submissions: closed (31 March 2024) | Viewed by 1371

Special Issue Editors

Prof. Dr. Lena Ruíz-Azuara

E-Mail Website
Guest Editor
Facultad de Quimica, Universidad Nacional Autónoma de México, Mexico City, Mexico
Interests: metallodrugs; cancer; activity descriptors; tropical neglected diseases
Prof. Dr. Carmen Mejía

E-Mail Website
Guest Editor
Facultad de Ciencias Naturales, Universidad Autónoma de Querétaro, Campus Juriquilla C.P. 76230, Querétaro, Mexico
Interests: cancer; apoptosis; molecular biology; cellular biology; action mechanism

Special Issue Information

Dear Colleagues,

We pleased to invite you to a Special Issue of Pharmaceutics (MDPI) entitled “Application of Metal-Based Complexes in Cancer Treatment”. The aim of this Special Issue is to compile the most recent innovative approaches on metallodrugs that include the design of new molecules with particular properties that may improve cancer treatment. The manuscripts can present studies of new targets, mechanisms of action, molecular and cellular studies, omics advances and differential gene expression, among other mechanisms. High-quality original research articles and reviews are welcome. Any approach to improve cancer treatment with a special type of formulation in order to preserve the activity of metallodrugs for cancer treatment is of interest. Research areas of this SI may include (but are not limited to) the following:

  1. Adult tumors;
  2. Child tumors;
  3. Essential metals;
  4. Non-essential metals.

We look forward to receiving your contributions.

Prof. Dr. Lena Ruíz-Azuara
Prof. Dr. Carmen Mejía
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • metallodrugs
  • mechanism of action
  • targets
  • pharmaceutical formulation

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 772 KiB  
Article
Synthesis and Preclinical Evaluation of Radiolabeled [103Ru]BOLD-100
by Barbara Happl, Marie Brandt, Theresa Balber, Katarína Benčurová, Zeynep Talip, Alexander Voegele, Petra Heffeter, Wolfgang Kandioller, Nicholas P. Van der Meulen, Markus Mitterhauser, Marcus Hacker, Bernhard K. Keppler and Thomas L. Mindt
Pharmaceutics 2023, 15(11), 2626; https://doi.org/10.3390/pharmaceutics15112626 - 15 Nov 2023
Cited by 1 | Viewed by 1000
Abstract
The first-in-class ruthenium-based chemotherapeutic agent BOLD-100 (formerly IT-139, NKP-1339, KP1339) is currently the subject of clinical evaluation for the treatment of gastric, pancreatic, colorectal and bile duct cancer. A radiolabeled version of the compound could present a helpful diagnostic tool. Thus, this study [...] Read more.
The first-in-class ruthenium-based chemotherapeutic agent BOLD-100 (formerly IT-139, NKP-1339, KP1339) is currently the subject of clinical evaluation for the treatment of gastric, pancreatic, colorectal and bile duct cancer. A radiolabeled version of the compound could present a helpful diagnostic tool. Thus, this study investigated the pharmacokinetics of BOLD-100 in more detail to facilitate the stratification of patients for the therapy. The synthesis of [103Ru]BOLD-100, radiolabeled with carrier added (c.a.) ruthenium-103, was established and the product was characterized by HPLC and UV/Vis spectroscopy. In order to compare the radiolabeled and non-radioactive versions of BOLD-100, both complexes were fully evaluated in vitro and in vivo. The cytotoxicity of the compounds was determined in two colon carcinoma cell lines (HCT116 and CT26) and biodistribution studies were performed in Balb/c mice bearing CT26 allografts over a time period of 72 h post injection (p.i.). We report herein preclinical cytotoxicity and pharmacokinetic data for BOLD-100, which were found to be identical to those of its radiolabeled analog [103Ru]BOLD-100. Full article
(This article belongs to the Special Issue Application of Metal-Based Complexes in Cancer Treatment)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop